MYC and acute myeloid leukemia: BRM011 promoted both apoptosis and differentiation through the regulation of MYC and other oncogenic pathways, including mTORC1, IL2/STAT5, KRAS, and EMT pathways, curtailing tumor growth in AML xenograft models with no evidence of toxicity.